These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32091358)

  • 1. Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada
    Langley JM; Gantt S; Quach C; Bettinger JA; Halperin SA; Mutch J; McNeil SA; Ward BJ; MacKinnon-Cameron D; Ye L; Marty K; Scheifele D; Brown E; Alcantara J;
    Emerg Infect Dis; 2020 Mar; 26(3):454-462. PubMed ID: 32091358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.
    Lujan E; Winter K; Rovaris J; Liu Q; Granoff DM
    Clin Infect Dis; 2017 Oct; 65(7):1112-1119. PubMed ID: 28582542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from mass vaccination response to meningococcal B outbreaks at US universities.
    Alderfer J; Isturiz RE; Srivastava A
    Postgrad Med; 2020 Sep; 132(7):614-623. PubMed ID: 32476532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.
    La EM; Talbird SE; Kanadanian KV; Huang L; Fain J; Srivastava A
    Hum Vaccin Immunother; 2019; 15(4):978-986. PubMed ID: 30526279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
    Rossi R; Beernink PT; Giuntini S; Granoff DM
    Clin Vaccine Immunol; 2015 Dec; 22(12):1227-34. PubMed ID: 26424832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.
    Folaranmi T; Rubin L; Martin SW; Patel M; MacNeil JR;
    MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(22):608-12. PubMed ID: 26068564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015-2016.
    Marjuki H; Chang HY; Topaz N; Whaley MJ; Vuong J; Chen A; Jenkins LT; Hu F; Schmink S; Retchless AC; Thomas JD; Acosta AM; McNamara LA; Soeters HM; Mbaeyi S; Wang X
    mBio; 2021 May; 12(3):. PubMed ID: 34006659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-component meningococcal serogroup B (MenB)-4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency.
    van den Broek B; van Els CACM; Kuipers B; van Aerde K; Henriet SS; de Groot R; de Jonge MI; Langereis JD; van der Flier M
    Clin Exp Immunol; 2019 Dec; 198(3):381-389. PubMed ID: 31487400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A physician's guide to the 2-dose schedule of MenB-FHbp vaccine.
    McDaniel A; Dempsey A; Srivastava A
    Hum Vaccin Immunother; 2019; 15(11):2729-2737. PubMed ID: 30932730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016.
    Patton ME; Stephens D; Moore K; MacNeil JR
    MMWR Morb Mortal Wkly Rep; 2017 May; 66(19):509-513. PubMed ID: 28520709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013-2018.
    Soeters HM; McNamara LA; Blain AE; Whaley M; MacNeil JR; Hariri S; Mbaeyi SA;
    Emerg Infect Dis; 2019 Mar; 25(3):434-440. PubMed ID: 30789140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: A retrospective analysis by vaccine and payer type.
    Packnett E; Irwin DE; Novy P; Watson PS; Whelan J; Moore-Schiltz L; Lucci M; Hogea C
    Vaccine; 2019 Sep; 37(39):5899-5908. PubMed ID: 31443990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
    Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
    Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College-Rhode Island, 2015-2016.
    Soeters HM; Whaley M; Alexander-Scott N; Kanadanian KV; MacNeil JR; Martin SW; McNamara LA; Sicard K; Vanner C; Vuong J; Wang X; Bandy U; Patel M;
    Clin Infect Dis; 2017 Apr; 64(8):1115-1122. PubMed ID: 28158417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Factor H Antibody Reactivity in Young Adults Vaccinated with a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein.
    Sharkey K; Beernink PT; Langley JM; Gantt S; Quach C; Dold C; Liu Q; Galvan M; Granoff DM
    mSphere; 2019 Jul; 4(4):. PubMed ID: 31270173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
    Beeslaar J; Absalon J; Balmer P; Srivastava A; Maansson R; York LJ; Perez JL
    Vaccine; 2018 Jun; 36(28):4004-4013. PubMed ID: 29861182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 20. Meningococcal Carriage Following a Vaccination Campaign With MenB-4C and MenB-FHbp in Response to a University Serogroup B Meningococcal Disease Outbreak-Oregon, 2015-2016.
    McNamara LA; Thomas JD; MacNeil J; Chang HY; Day M; Fisher E; Martin S; Poissant T; Schmink SE; Steward-Clark E; Jenkins LT; Wang X; Acosta A;
    J Infect Dis; 2017 Nov; 216(9):1130-1140. PubMed ID: 28968661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.